The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.

A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00154362

Enrollment

Registered

2005-09-12

Start date

2003-04-30

Completion date

2004-10-31

Last updated

2011-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Conduct Disorder

Keywords

Oxcarbazepine, conduct disorder, adolescents

Brief summary

Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.

Interventions

DRUGOxcarbazepine

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

6 Years to 16 Years

Healthy volunteers

Inclusion criteria

* History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified * Score \>8 on the Impulsivity Rating Scale

Exclusion criteria

* Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified * Treatment with antiepileptic medications Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Percentage reduction on Impulsivity Rating Scale (IRS)	—

Secondary

Measure	Time frame
Percent reduction in the Modified Overt Aggression Scale (MOAS)	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026